35969-51-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Ethoxy-2-oxoethyl)nicotinic acid is used as a building block for the synthesis of various drugs and active pharmaceutical ingredients due to its unique structure containing both a pyridine ring and an ethoxy-oxoethyl group.
Used in Cardiovascular Disease Treatment:
2-(2-Ethoxy-2-oxoethyl)nicotinic acid is used as a therapeutic agent for the treatment of cardiovascular diseases, leveraging its potential to improve cardiovascular health.
Used in Metabolic Disorder Treatment:
2-(2-Ethoxy-2-oxoethyl)nicotinic acid is used as a treatment for metabolic disorders, potentially aiding in the regulation of metabolic processes in the body.
Used in Inflammation Management:
2-(2-Ethoxy-2-oxoethyl)nicotinic acid is used as an anti-inflammatory agent, potentially helping to reduce inflammation in various conditions.
Used in Antioxidant and Neuroprotective Applications:
2-(2-Ethoxy-2-oxoethyl)nicotinic acid is used for its potential antioxidant properties, which may help protect cells from oxidative damage, and for its neuroprotective effects, potentially safeguarding the nervous system from degeneration.

InChI:InChI=1/C10H11NO4/c1-2-15-9(12)6-8-7(10(13)14)4-3-5-11-8/h3-5H,2,6H2,1H3,(H,13,14)

Upstream product

• 2942-59-8 2-chloronicotinic acid 
• 141-97-9 ethyl acetoacetate 
• 35905-85-2 2-bromonicotinic acid 
• 105-53-3 diethyl malonate 
• 3430-17-9 2-bromo-3-picoline 
• 1603-40-3 3-methylpyridin-2-ylamine 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 399017-38-0 7-(3-carboxypyridin-2-yl)quinolizinium-1-carboxylate inner salt 
• 19693-54-0 6-Methyl-1,6-naphthyridin-5-(6H)-on 

Relevant academic research and scientific papers

MODULATORS OF HEMOGLOBIN

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin and methods for their use in treating disorders mediated by hemoglobin. (Formula (I))

Photophysical behavior of a novel 4-aza-indole derivative in different solvents: reverse solvatochromism

The photophysical properties of a new 4-aza-indole derivative [ethyl 1-((2-(2-ethoxy-2-oxoethyl)pyridin-3-yl)carbamoyl)-2-hydroxy-1H-pyrrolo-[3,2-b]pyridine-3-carboxylate, 12] were determined in different solvents. Compound 12 exhibited an absorbance peak at 340–360?nm with high fluorescence intensity in the wavelength range from 405 to 417?nm in all solvents except N,N-dimethylformamide (DMF). Compound 12 exhibited reverse solvatochromism behavior depending on the solvent polarity. Furthermore, compound 12 showed very high quantum yield in all solvents independent of their polarity. The results suggest that this novel dye could be used for many applications, e.g., as a labeling agent and in bio- or analytical sensors and/or optoelectronic devices.

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders

Phosphodiesterase (PDE) 2A inhibitors have emerged as a novel mechanism with potential therapeutic option to ameliorate cognitive dysfunction in schizophrenia or Alzheimer's disease through upregulation of cyclic nucleotides in the brain and thereby achieve potentiation of cyclic nucleotide signaling pathways. This article details the expedited optimization of our recently disclosed pyrazolo[1,5-a]pyrimidine lead compound 4b, leading to the discovery of clinical candidate 36 (TAK-915), which demonstrates an appropriate combination of potency, PDE selectivity, and favorable pharmacokinetic (PK) properties, including brain penetration. Successful identification of 36 was realized through application of structure-based drug design (SBDD) to further improve potency and PDE selectivity, coupled with prospective design focused on physicochemical properties to deliver brain penetration. Oral administration of 36 demonstrated significant elevation of 3′,5′-cyclic guanosine monophosphate (cGMP) levels in mouse brains and improved cognitive performance in a novel object recognition task in rats. Consequently, compound 36 was advanced into human clinical trials.

Synthesis of new 4-aza-indoles via acyl azides

We hereby report the preparation of new azaindole derivatives starting from 2-(2-ethoxy-2-oxoethyl)nicotinic acid. Conversion of a half ester into acyl azide followed by Curtius rearrangement gave the corresponding isocyanate. Trapping of the isocyanate with different nucleophiles produced urea and urethane derivatives. Intramolecular cyclization reactions gave the target compounds.

SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans.

7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS

The present invention relates to a compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.

7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS

A compound of formula (I) or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.